Post-Marketing Analysis of Peripheral Neuropathy Burden with New-Generation Proteasome Inhibitors Using the FDA Adverse Event Reporting System

Proteasome inhibitors (PIs) are an integral component of multiple myeloma therapies. Peripheral neuropathy (PN) is a well-known consequence of PIs, most frequently reported with earlier generations such as Bortezomib (BTZ). There is a paucity of data highlighting the risk of developing PN in the new...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Syeda A. Mina, Ibrahim Muhsen, Ethan Burns, Humaira Sarfraz, Sai Ravi Pingali, Jiaqiong Xu, Shahrukh K. Hashmi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Turkish Society of Hematology 2021-08-01
coleção:	Turkish Journal of Hematology
Assuntos:	multiple myeloma proteasome inhibitors peripheral neuropathy
Acesso em linha:	https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-28913
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!